Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
MetadataShow full item record
CitationKonstantinopoulos, Panagiotis A., and Ursula A. Matulonis. 2013. “Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer.” Frontiers in Oncology 3 (1): 296. doi:10.3389/fonc.2013.00296. http://dx.doi.org/10.3389/fonc.2013.00296.
AbstractEpithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States. Although important advances in surgical and chemotherapeutic strategies over the last three decades have significantly improved the median survival of EOC patients, the plateau of the survival curve has not changed appreciably. Given that EOC is a genetically and biologically heterogeneous disease, identification of specific molecular abnormalities that can be targeted in each individual ovarian cancer on the basis of predictive biomarkers promises to be an effective strategy to improve outcome in this disease. However, for this promise to materialize, appropriate preclinical experimental platforms that recapitulate the complexity of these neoplasms and reliably predict antitumor activity in the clinic are critically important. In this review, we will present the current status and evolution of preclinical models of EOC, including cell lines, immortalized normal cells, xenograft models, patient-derived xenografts, and animal models, and will discuss their potential for oncology drug development.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879349
- HMS Scholarly Articles